Physician profile
Keith T Goldstein
NPI 1275506453
$721.77
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.73 · 2020: $149 · 2021: $248 · 2022: $251.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.00 | 2021 | |
| Philips North America LLC | $137.19 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $115.20 | 2019-2020 | |
| Glaxosmithkline, LLC. | $95.08 | 2020-2022 | |
| Vapotherm INC | $34.49 | 2019 | |
| Medtronic, INC. | $32.49 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.89 | 2020 | |
| Jazz Pharmaceuticals INC. | $14.62 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.